Characterization of RNABP, an RNA binding protein that associates with RNase L

Journal of Interferon and Cytokine Research

Volumn 20, Issue 7, 2000, Pages 635-644

  Le Roy, Florence ^a   Laskowska, Anna ^a   Silhol, Michelle ^a   Salehzada, Tamim ^a,b   Bisbal, Catherine ^a,b  

^a INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

^b INSTITUTE OF HUMAN GENETICS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON; RIBONUCLEASE; RNA BINDING PROTEIN;

ANIMAL CELL; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION;

ADENINE NUCLEOTIDES; ANIMALS; ANTIBODIES, MONOCLONAL; CELL DIFFERENTIATION; CELL TRANSFORMATION, VIRAL; CHROMATOGRAPHY, AFFINITY; CHROMATOGRAPHY, GEL; ENCEPHALOMYOCARDITIS VIRUS; ENDORIBONUCLEASES; HELA CELLS; HUMANS; INTERFERON TYPE I; LEUKEMIA, ERYTHROBLASTIC, ACUTE; MICE; MOLECULAR WEIGHT; OLIGORIBONUCLEOTIDES; RNA-BINDING PROTEINS; TUMOR CELLS, CULTURED; U937 CELLS; VESICULAR STOMATITIS-INDIANA VIRUS;

ANIMALIA; ENCEPHALOMYOCARDITIS VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 0033911682     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/107999000414817     Document Type: Article

References (43)

1. BISBAL, C. (1997). RNase L: effector nuclease of an activatable RNA degradation system in mammals. Prog. Mol. Subcell. Biol. 18, 19-34.
2. SILVERMAN, R.H. ( 1997). 2-5 A-Dependent RNase L: a regulated endoribonuclease in the interferon system. In: Ribonucleases: Structure and Functions. G. D' Alessio and J.F. Riordan (eds.) New York: Academic Press, Inc., pp. 515-551.
3. KERR, I.M., and BROWN, R.E. (1978). pppA2′p5′-A2′p5′A: an inhibitor of protein synthesis synthesized with an enzyme fraction from interferon-treated cells. Proc. Natl. Acad. Sci. USA 75, 256-260.
4. FLOYD, S.G., SLATTERY, E., and LENGYEL, P. (1981). Interferon action: RNA cleavage pattern of a (2′-5′)oligoadenylate-dependent endonuclease. Science 212, 1030-1032.
5. DONG. B., and SILVERMAN, R.H. (1995). 2-5A-Dependent RNase molecules dimerize during activation by 2-5A. J. Biol. Chem. 270, 4133-4137.
6. LI, X.L., BLACKFORD, J.A., and RASSEL, B.A. (1998). RNase L mediates the antiviral effect of interferon through a selective reduction in viral RNA during encephalomyocarditis virus infection. J. Virol. 72, 2752-2759.
7. GRIBAUDO, G., LEMBO, D., CAVALLO, G., LANDOLFO, S., and LENGYEL, P. (1991). Interferon action: binding of viral RNA to the 40-kilodalton 2′-5′-oligoadenylate synthetase in interferontreated HeLa cells infected with encephalomyocarditis virus. J. Virol. 65, 1748-1757.
8. MAITRA, R.K., and SILVERMAN, R.H. (1998). Regulation of human immunodeficiency virus replication by 2′,5′-oligoadeny-late-dependent RNase L. J. Virol. 72, 1146-1152.
9. MARTINAND, C., MONTA VON, C., SALEHZADA, T., SILHOL, M., LEBLEU, B., and BISBAL, C. (1999). RNase L inhibitor is induced during human immunodeficiency virus type 1 infection and down regulates the 2-5A/RNase L pathway in human T cells. J. Virol. 73, 290-296.
10. BISBAL, C., MARTINAND, C., SILHOL, M., LEBLEU, B., and SALEHZADA, T. (1995). Cloning and characterization of a RNAse L inhibitor. A new component of the interferon-regulated 2-5A pathway. J. Biol. Chem. 270, 13308-13317.
11. MARTINAND, C., SALEHZADA, T., SILHOL, M., LEBLEU, B., and BISBAL, C. (1998). RNase L inhibitor (RLI) antisense constructions block partially the down regulation of the 2-5A/RNase L pathway in encephalomyocarditis-virus (EMCV)-infected cells. Eur. J. Biochem. 254, 238-247.
12. SLATTERY, E., GHOSH, N., SAMANTA, H., and LENGYEL, P. (1979). Interferon, double-stranded RNA, and RNA degradation: activation of an endonuclease by (2′-5′)An. Proc. Natl. Acad. Sci. USA 76, 4778-4782.
13. WRESCHNER, D.H., SILVERMAN, R.H., JAMES, T.C., GILBERT, C.S., and KERR, I.M. (1982). Affinity labeling and characterization of the ppp(A2′p)nA-dependent endoribonuclease from different mammalian sources. Eur. J. Biochem. 124, 261-268.
14. ZHOU, A., HASSEL, B.A., and SILVERMAN, R.H. (1993). Expression cloning of 2-5A-dependent RNase: a uniquely regulated mediator of interferon action. Cell 72, 753-765.
15. NAIK, S., PARANJAPE, J.M., and SILVERMAN, R.H. (1998). RNase L dimerization in a mammalian two-hybrid system in response to 2′,5′-oligoadenylates. Nucleic Acids Res. 26, 1522-1527.
16. FLOYD, S.G., YOSHIE, O., and LENGYEL, P. (1982). Interferon action. Covalent linkage of (2′-5′)pppApApA(32PjpCp to (2′-5′)(A)n-dependent ribonucleases in cell extracts by ultraviolet irradiation. J. Biol. Chem. 257, 8584-8587.
17. BISBAL, C., SALEHZADA, T., LEBLEU, B., and BAYARD, B. (1989). Characterization of two murine (2′-5′)(A)n-dependent en- donucleases of different molecular mass. Eur. J. Biochem. 179, 595-602.
18. WRESCHNER, D.H., JAMES, T.C., SILVERMAN, R.H., and KERR, I.M. (1981). Ribosomal RNA cleavage, nuclease activation and 2-5A(ppp(A2′p)nA) in interferon-treated cells. Nucleic Acids Res. 9, 1571-1581.
19. SALEHZADA, T., SILHOL, M., STEFF, A.M., LEBLEU, B., and BISBAL, C. (1993). 2′,5′-Oligoadenylate-dependent RNase L is a dimer of regulatory and catalytic subunits. J. Biol. Chem. 268, 7733-7740.
20. YAFFE, D., and SAXEL, O. (1977). Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature 270, 725-727.
21. PINSET, C., MONTARRAS, D., CHENEVERT, J., MINTY, A., BARTON, P., LAURENT, C., and GROS, F. (1988). Control of myogenesis in the mouse myogenic C2 cell line by medium composition and by insulin: characterization of permissive and inducible C2 myoblasts. Differentiation 38, 28-34.
22. WHITAKER, J.R., and GRANUM, P.E. (1980). An absolute method for protein determination based on difference in absorbance at 235 and 280 nm. Anal. Biochem. 109, 156-159.
23. TOWBIN, H., STAEHELIN, T., and GORDON, J. (1979). Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 76, 4350-4354.
24. KNIGHT, M., CAYLEY, P.J., SILVERMAN, R.H., WRESCHNER, D.H., GILBERT, C.S., BROWN, R.E., and KERR, I.M. (1980). Radioimmune, radiobinding and HPLC analysis of 2-5A and related oligonucleotides from intact cells. Nature 288, 189-192.
25. LAEMMLI, U.K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.
26. BAYARD, B., BISBAL, C., SILHOL, M., CNOCKAERT, J., HUEZ, G., and LEBLEU, B. (1984). Increased stability and antiviral activity of 2′-O-phosphoglyceryl derivatives of (2′-5′)oligo(adenylate). Eur. J. Biochem. 142, 291-298.
27. MILHAUD, P.G., SILHOL, M., FAURE, T., and MILHAUD, X. (1983). Numerical tables for the direct estimation of virus titres by the maximum likelihood method. Ann. Virol. (Inst. Pasteur) 134, 405-416.
28. BANDYOPADHYAY, R., COUTTS, M., KROWCZYNSKA, A., and BRAWERMAN, G. (1990). Nuclease activity associated with mammalian mRNA in its native state: possible basis for selectivity in mRNA decay. Mol. Cell. Biol. 10, 2060-2069.
29. HOVANESSIAN, A.G., LAURENT, A.G., CHEBATH, J., GALABRU, J., ROBERT, N., and SVAB, J. (1987). Identification of 69-kd and 100-kd forms of 2-5A synthetase in interferon-treated human cells by specific monoclonal antibodies. EMBO J. 6, 1273-1280.
30. SAMBROOK, J., FRISCH, E.F., and MANIATIS, T. (1982). Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
31. DONG, B., and SILVERMAN, R.H. (1997). A bipartite model of 2-5A-dependent RNase L. J. Biol. Chem. 272, 22236-22242.
32. DEFILIPPI, P., HUEZ, G., VERHAEGEN, L.M., DE, C.E., TORRENCE, P., and CONTENT, J. (1985). Antiviral activity towards VS V and Mengo virus of a chemically stabilized 2-5A analog upon microinjection into HeLa cells. Prog. Clin. Biol. Res. 202, 141-146.
33. DEFILIPPI, P., HUEZ, G., VERHAEGEN, L.M., DE, C.E., IMAI, J., TORRENCE, P., and CONTENT, J. (1986). Antiviral activity of a chemically stabilized 2-5A analog upon microinjection into HeLa cells. FEBS Lett. 198, 326-332.
34. COCCIA, E.M., ROMEO, G., NISSIM, A., MARZIALI, G., ALBERTINI, R., AFFABRIS, E., BATTISTINI, A., FIORUCCI, G., ORSATTI, R., ROSSI, G.B., et al. (1990). A full-length murine 2-5A synthetase cDNA transfected in NIH-3T3 cells impairs EMCV but not VSV replication. Virology 179, 228-233.
35. SEN, G.C., and LENGYEL, P. (1992). The interferon system. A bird's eye view of its biochemistry. J. Biol. Chem. 267, 5017-5020.
36. SILVERMAN, R.H., CAYLEY, P.J., KNIGHT, M., GILBERT, C.S., and KERR, I.M. (1982). Control of the ppp(a2′p)nA system in HeLa cells. Effects of interferon and virus infection. Eut. J. Biochem. 124, 131-138.
37. CAYLEY, P.J., KNIGHT, M., and KERR, I.M. (1982). Virusmediated inhibition of the ppp(A2′p)nA system and its prevention by interferon. Biochem. Biophys. Res. Commun. 104, 376-382.
38. SILVERMAN, R.H., CIRINO, N.M. (1997). RNA decay by the interferon-regulated 2-5A system as a host defense against viruses. In: mRNA Metabolism and Post-Transcriptional Gene Regulation. J.B. Hartford and D.R. Morris (eds.) New York.: Wiley-Liss, Inc., pp. 295-309.
39. BISBAL, C., SILHOL, M., LEMAITRE, M., BAYARD, B., SALEHZADA, T., LEBLEU, B., PERREE, T.D., and BLACKBURN, M.G. (1987). 5′-Modified agonist and antagonist (2′-5′)(A)n analogues: synthesis and biological activity. Biochemistry 26, 5172-5178.
40. HASSEL, B.A., ZHOU, A., SOTOMAYOR, C., MARAN, A., and SILVERMAN, R.H. (1993). A dominant negative mutant of 2-5A-dependent RNase suppresses antiproliferative and antiviral effects of interferon. EMBO J. 12, 3297-3304.
41. WATLING, D., SERAFINOWSKA, H.T., REESE, C.B., and KERR, I.M. (1985). Analogue inhibitor of 2-5A action: effect on the interferon-mediated inhibition of encephalomyocarditis virus replication. EMBO J. 4, 431-436.
42. DONG, B., XU, L., ZHOU, A., HASSEL, B.A., LEE, X., TORRENCE, P.F., and SILVERMAN, R.H. (1994). Intrinsic molecular activities of the interferon-induced 2-5A-dependent RNase. J. Biol. Chem. 269, 14153-14158.
43. PLAYER, M.R., and TORRENCE, P.P. (1998). The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation. Pharmacol. Ther. 78, 55-113.